Maridebart Cafraglutide Dual Myostatin-GLP-1 Therapy Preserves Muscle During 20% Weight Loss

Why Is Muscle Loss a Problem With Current GLP-1 Weight Loss Drugs?

A growing body of evidence has highlighted that GLP-1 receptor agonists, while highly effective for weight loss, result in significant lean muscle mass reduction alongside fat loss. Body composition analyses from major GLP-1 clinical trials, including the STEP program evaluating semaglutide, have shown that approximately 25-40% of total weight lost can consist of lean tissue, including skeletal muscle. A 2021 sub-analysis of the STEP 1 trial published in the New England Journal of Medicine noted meaningful reductions in lean mass alongside fat mass over 68 weeks of treatment. This is particularly concerning for adults over 60, where muscle loss can accelerate sarcopenia, increase fall risk, and reduce functional independence.

Researchers have been exploring myostatin inhibition as a strategy to counteract this muscle loss. Myostatin is a protein that acts as a negative regulator of muscle growth—blocking it promotes muscle protein synthesis and hypertrophy. The concept of combining a myostatin inhibitor with a GLP-1 receptor agonist aims to achieve the metabolic and appetite-suppressing benefits of GLP-1 agonism while counteracting the catabolic effect on muscle tissue. Early-phase clinical trials of such combinations have used DEXA body composition scans to track lean mass changes, with preliminary data suggesting that dual therapy may substantially reduce the proportion of lean tissue lost compared to GLP-1 monotherapy.

What Were the Early Clinical Results of Dual Myostatin-GLP-1 Therapy?

Phase 2 clinical research evaluating the combination of anti-myostatin antibodies with GLP-1 receptor agonists has shown encouraging preliminary results. In early-phase obesity trials, dual therapy groups have achieved substantial total body weight reductions while retaining a significantly greater proportion of lean muscle mass than participants receiving GLP-1 agonist monotherapy. These trials typically enrolled adults with obesity (BMI 30-45) and measured body composition outcomes over treatment periods of up to 48 weeks.

Functional measures of muscle quality, such as grip strength, have also shown less decline in combination therapy groups compared to GLP-1 monotherapy. Resting metabolic rate, which typically decreases with weight loss due to reduced lean mass, appears to be better preserved with dual therapy. The safety profile of myostatin inhibitors in combination with GLP-1 agonists has generally been manageable, with injection site reactions and standard GLP-1 gastrointestinal effects being the most commonly reported adverse events. Several pharmaceutical companies, including Scholar Rock, are advancing myostatin-targeting programs, and regulatory agencies have shown interest in therapies that address body composition during weight loss. Further Phase 3 studies will be needed to confirm these early findings.